Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Indatuximab ravtansine |
| Trade Name | |
| Synonyms | BT062|BT-062|BT 062 |
| Drug Descriptions |
Indatuximab Ravtansine (BT062) is an antibody-drug conjugate (ADC) comprising an antibody that targets CD138 linked to the cytotoxic drug DM4, which potentially inhibits growth of CD138-expressing tumors (PMID: 29666962, PMID: 30930134). |
| DrugClasses | |
| CAS Registry Number | 1238517-16-2 |
| NCIT ID | C78840 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + Indatuximab ravtansine | Docetaxel Indatuximab ravtansine | 0 | 0 |
| Indatuximab ravtansine | Indatuximab ravtansine | 0 | 0 |
| Indatuximab ravtansine + Paclitaxel | Indatuximab ravtansine Paclitaxel | 0 | 0 |